Nothing Special   »   [go: up one dir, main page]

SG11202000073XA - Anti-cd8 antibodies and uses thereof - Google Patents

Anti-cd8 antibodies and uses thereof

Info

Publication number
SG11202000073XA
SG11202000073XA SG11202000073XA SG11202000073XA SG11202000073XA SG 11202000073X A SG11202000073X A SG 11202000073XA SG 11202000073X A SG11202000073X A SG 11202000073XA SG 11202000073X A SG11202000073X A SG 11202000073XA SG 11202000073X A SG11202000073X A SG 11202000073XA
Authority
SG
Singapore
Prior art keywords
new york
international
tarrytown
saw mill
antibodies
Prior art date
Application number
SG11202000073XA
Inventor
Jason T Giurleo
Dangshe Ma
William Olson
Richard Tavare
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63143411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202000073X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202000073XA publication Critical patent/SG11202000073XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

International Patent Classification: A61K 49/00 (2006.01) C07K 16/28 (2006.01) A61K 49/16 (2006.01) GO1N 33/53 (2006.01) A61K 51/10 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/043343 C Human CDS+ T-cells Cynomolgus Monkey T-cells Ir a rnAtil -0- H4sH Isotype -12 -11 -.10 Concentration of Antibody Log (M) 3 -12 -11 -10 -- -8 Concentration of Antibody Log (M) rriAla1 mAbl, EC5O 3,694e-010 EC50 3.287e-010 rnAbl H4sH Isotype (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo v1111111111 Ho Eno En Hs (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/023148 Al (43) International Publication Date 31 January 2019 (31.01.2019) WIPO I PCT er Road, Tarrytown, New York 10591 (US). THURSTON, Gavin; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (74) Agent: CROWLEY-WEBER, Cara L.; FisherBroyles, LLP, 26844 E. Quarto Pl., Aurora, Colorado 80016 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 23 July 2018 (23.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/536,239 24 July 2017 (24.07.2017) US 62/660,902 20 April 2018 (20.04.2018) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (72) Inventors: GIURLEO, Jason T.; c/o Regeneron Pharma- ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). MA, Dangshe; c/o Regeneron Phar- maceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). OLSON, William; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tar- rytown, New York 10591 (US). TAVARE, Richard; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Riv- (54) Title: ANTI-CD8 ANTIBODIES AND USES THEREOF Figure 1 (57) : Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample. [Continued on next page] WO 2019/023148 Al MIDEDIMOHNORMIE111101110M11111111111101111111111111111111 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11202000073XA 2017-07-24 2018-07-23 Anti-cd8 antibodies and uses thereof SG11202000073XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762536239P 2017-07-24 2017-07-24
US201862660902P 2018-04-20 2018-04-20
PCT/US2018/043343 WO2019023148A1 (en) 2017-07-24 2018-07-23 Anti-cd8 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11202000073XA true SG11202000073XA (en) 2020-02-27

Family

ID=63143411

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000073XA SG11202000073XA (en) 2017-07-24 2018-07-23 Anti-cd8 antibodies and uses thereof

Country Status (17)

Country Link
US (3) US10730944B2 (en)
EP (1) EP3658193A1 (en)
JP (2) JP7304846B2 (en)
KR (1) KR20200031645A (en)
CN (1) CN110997013B (en)
AU (1) AU2018307744A1 (en)
BR (1) BR112020001360A2 (en)
CA (1) CA3070796A1 (en)
CL (1) CL2020000192A1 (en)
CO (1) CO2020000680A2 (en)
IL (1) IL271901B1 (en)
MA (1) MA49683A (en)
MX (1) MX2020000916A (en)
MY (1) MY197688A (en)
PH (1) PH12020550008A1 (en)
SG (1) SG11202000073XA (en)
WO (1) WO2019023148A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US10730944B2 (en) 2017-07-24 2020-08-04 Regeneron Pharmaceuticals, Inc. Anti-CD8 antibodies and uses thereof
IL294589A (en) * 2020-01-10 2022-09-01 Fusion Pharmaceuticals Inc Sustained immunotherapy
CN113563473A (en) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
CN111413298A (en) * 2020-05-27 2020-07-14 深圳市天安至远传感科技有限公司 Optical fiber surface plasma resonance sensor, preparation method and detection system
JP2023535708A (en) * 2020-07-21 2023-08-21 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド CD8 binding polypeptides and uses thereof
WO2022036079A1 (en) 2020-08-13 2022-02-17 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
CN114112868A (en) * 2020-08-26 2022-03-01 上海睿昂基因科技股份有限公司 Flow cytometry kit for monitoring tumor-related immune microenvironment and monitoring method
US12024559B2 (en) 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
AU2022206324A1 (en) 2021-01-11 2023-07-20 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
EP4320242A1 (en) 2021-04-08 2024-02-14 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
US20240254238A1 (en) * 2021-05-26 2024-08-01 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
CN114230665B (en) * 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8 alpha binding polypeptides and uses thereof
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
JP2024536722A (en) 2021-09-03 2024-10-08 ジーオー セラピューティクス，インコーポレイテッド Anti-glyco-CMET antibodies and uses thereof
KR20240101546A (en) 2021-09-03 2024-07-02 고 테라퓨틱스, 인크. Anti-glyco-LAMP1 antibodies and uses thereof
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CN115337413B (en) * 2022-08-08 2023-08-22 中国科学院近代物理研究所 Preparation and application of radioactive molecular probe for non-small cell lung cancer diagnosis
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024188355A1 (en) 2023-03-16 2024-09-19 Itabmed Biopharmaceutical (Shanghai) Co., Ltd. Multispecific antigen binding proteins and uses thereof
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR20040088572A (en) 2002-03-01 2004-10-16 이뮤노메딕스, 인코오포레이티드 Bispecific antibody point mutations for enhancing rate of clearance
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006050058A2 (en) 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
US20080193376A1 (en) 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
WO2008124467A1 (en) 2007-04-06 2008-10-16 Macrocyclics Bifunctional hydroxamic acid ligands and method of synthesis
MX2010007023A (en) 2007-12-21 2010-09-30 Schering Corp C20-c21 substituted glucocorticoid receptor agonists.
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
NZ590197A (en) 2008-06-06 2012-10-26 Baylor Res Inst Use of anti-CD8 antibodies to block activation of auto reactive T cells and generation of tolerogenic CD8 regulatory T-cells
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
NZ610976A (en) 2010-12-20 2015-07-31 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
US10668162B2 (en) 2012-01-06 2020-06-02 Linxis B.V. Method for preparing cell targeting conjugates, and the complexes obtained
WO2013138696A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 complexes, methods of labeling cells, labeled cells, kits, and methods of use thereof
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
RU2014148162A (en) 2012-05-01 2016-06-20 Дженентек, Инк. ANTI-PMEL17 ANTIBODIES AND THEIR IMMUNO CONJUGATES
KR101718200B1 (en) 2012-05-21 2017-03-21 제넨테크, 인크. ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
US20150191543A1 (en) 2012-08-06 2015-07-09 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
US20150246146A1 (en) 2012-10-25 2015-09-03 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
JP6490574B2 (en) 2013-02-28 2019-03-27 国立研究開発法人国立がん研究センター Antibodies against insoluble fibrin
CN105163765A (en) * 2013-03-13 2015-12-16 伊麦吉纳博公司 Antigen binding constructs to CD8
WO2014159087A1 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
CN105189552B (en) 2013-03-14 2019-08-02 基因泰克公司 Anti- B7-H4 antibody and immunoconjugates
JP2016527202A (en) 2013-06-10 2016-09-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． How to treat cancer
AR096687A1 (en) 2013-06-24 2016-01-27 Genentech Inc ANTI-FCRH5 ANTIBODIES
FR3008408B1 (en) 2013-07-11 2018-03-09 Mc Saf NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
WO2015061209A1 (en) 2013-10-21 2015-04-30 Genentech, Inc. ANTI-Ly6E ANTIBODIES AND METHODS OF USE
PT3071595T (en) 2013-11-19 2019-06-11 Fredax Ab Humanised anti kallikrein-2 antibody
JP6502942B2 (en) 2013-12-13 2019-04-17 ジェネンテック， インコーポレイテッド Anti-CD33 antibody and immunoconjugate
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
DK3131585T3 (en) 2014-03-19 2020-10-19 Univ Zuerich MULTIDENTATE, BY-FUNCTIONAL CHELATING AGENTS FOR RADIONUCLID COMPLEX FORMATION IN DIAGNOSTICS AND THERAPY
WO2015179658A2 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
CA2949936C (en) 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
CA2949982A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
PL3177640T3 (en) 2014-08-08 2020-11-02 The Board Of Trustees Of The Leland Stanford Junior University High affinity pd-1 agents and methods of use
AR101848A1 (en) 2014-09-12 2017-01-18 Genentech Inc ANTI-B7-H4 AND IMMUNOCATE PLAYERS
WO2016040723A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
MA40579A (en) 2014-09-12 2016-03-17 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
CN104360049B (en) 2014-09-22 2016-08-17 重庆医科大学附属儿童医院 A kind of method of T lymphocyte immunity typing and test kit
WO2016058056A1 (en) 2014-10-16 2016-04-21 The University Of Melbourne Novel imaging composition and uses thereof
US10406251B2 (en) 2014-11-25 2019-09-10 Bristol-Myers Squibb Company PD-L1 binding polypeptides for imaging
WO2016144873A2 (en) 2015-03-06 2016-09-15 Mayo Foundation For Medical Education And Research Methods for cell labeling and medical imaging
NL2014423B1 (en) 2015-03-09 2016-10-13 Linxis B V Method for removing weakly bound functional moieties from cell targeting conjugates.
ES2941968T3 (en) 2015-10-01 2023-05-29 The Whitehead Institute For Biomedical Res Antibody labeling
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
MA53402A (en) 2016-05-19 2021-06-02 Bristol Myers Squibb Co IMMUNOMODULATORS FOR PET IMAGING
WO2017213494A1 (en) 2016-06-06 2017-12-14 Linxis B.V. Cell targeting conjugates
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
EP3266465A1 (en) 2016-07-06 2018-01-10 Julius-Maximilians-Universität Würzburg Immune complexes
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
KR102396334B1 (en) 2016-07-18 2022-05-09 위스콘신 얼럼나이 리서어치 화운데이션 Radiohalogenated Agents for In Situ Immunomodulatory Cancer Vaccination
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
EP4026849A1 (en) 2016-09-26 2022-07-13 Ensemble Group Holdings Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors
US11103603B2 (en) 2016-10-20 2021-08-31 The University Of North Carolina At Chapel Hill 18F-labeled compounds for PET imaging and uses thereof
EP3565555A4 (en) 2016-11-07 2021-03-17 VIDAC Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (hk2)-expressing cancers
US10730944B2 (en) 2017-07-24 2020-08-04 Regeneron Pharmaceuticals, Inc. Anti-CD8 antibodies and uses thereof

Also Published As

Publication number Publication date
CO2020000680A2 (en) 2020-01-31
IL271901B1 (en) 2024-11-01
MA49683A (en) 2020-06-03
US20210147542A1 (en) 2021-05-20
JP7304846B2 (en) 2023-07-07
CL2020000192A1 (en) 2020-08-14
MX2020000916A (en) 2020-09-10
MY197688A (en) 2023-07-05
US12077587B2 (en) 2024-09-03
KR20200031645A (en) 2020-03-24
US20230159639A1 (en) 2023-05-25
BR112020001360A2 (en) 2020-08-11
AU2018307744A1 (en) 2020-02-13
CA3070796A1 (en) 2019-01-31
WO2019023148A1 (en) 2019-01-31
EP3658193A1 (en) 2020-06-03
US11525001B2 (en) 2022-12-13
CN110997013B (en) 2022-09-20
CN110997013A (en) 2020-04-10
JP2023121798A (en) 2023-08-31
IL271901A (en) 2020-02-27
US10730944B2 (en) 2020-08-04
PH12020550008A1 (en) 2020-10-12
JP2020534250A (en) 2020-11-26
US20190023790A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
SG11202000073XA (en) Anti-cd8 antibodies and uses thereof
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201808797XA (en) T cell receptors
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201908796XA (en) Improved antigen binding receptors
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201907278VA (en) Anti-tigit antibodies
SG11201906341XA (en) Improved serum albumin binders
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201909749PA (en) Oncolytic virotherapy and immunotherapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201907319QA (en) Gamma delta t cells and a method of augmenting the tumoricidal activity of the same